On November 12, 2015, Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development, and commercialization of first-in-class therapeutics, announced its business and financial update for the third quarter ended September 30, 2015. Operational highlights included presentation of the company’s positive six-month DYNAMIC (Dilated cardiomyopathy Intervention with Allogeneic MyocardIally-Regenerative Cells) clinical trial results of its cardiosphere derived cell (CDC) therapy, CAP-1002, for the treatment of advanced heart failure. In addition, the company appointed Deborah Ascheim, M.D., as its Chief Medical Officer. Dr. Ascheim is a heart failure cardiologist with significant experience directing national and international clinical trials. "We have made significant advances for the CAP-1002 clinical development program this quarter," said Linda Marban (photo), Ph.D., the President, CEO, and Dirctor of Capricor. "Data from the DYNAMIC clinical trial presented at the American Heart Association Scientific Sessions earlier this week confirmed the bioactivity of our CDC therapy as seen in earlier clinical trials. In addition, the multi-vessel intracoronary infusion technique used in the DYNAMIC trial was safe and well tolerated and will be used in our HOPE-Duchenne clinical trial, which is now open for enrollment. We are encouraged by the concordance of the clinical data with the physiologic outcomes in the previous CDC clinical trials, CADUCEUS, ALLSTAR and now DYNAMIC, and are hopeful that the reduction of scarring in damaged hearts will also translate into positive outcomes for DMD-related cardiomyopathy patients in the HOPE-Duchenne clinical trial." In its announcement, Capricor also gave an update of its Clinical Development Program.Login Or Register To Read Full Story